AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT03175458 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sinus lift,implant placement,bovine bone
Description: sinus membrane elevation then placement of the implants together with deproteinized bovine bone substitute as a graft material for augmentation
Study NCT02194491 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: [11C]AS2471907
Description: intravenous radiotracer
Study NCT01406717 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPIL1033
Description: 5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.
Study NCT01406717 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 5 mcg twice daily for the first 4 weeks and 10 mcg twice daily for the remaining 20 weeks. To be self-administered twice daily.
Study NCT02194491 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Positron Emission Tomography (PET)
Description: Imaging scanning procedure
Study NCT03596294 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Saline (0.9% sodium chloride)
Description: Single i.v infusion of 500 mL saline for 30 min
Study NCT02194491 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3662
Description: oral
Study NCT02825810 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cervical motor control
Description: Intervention will consist in a tailored exercise training following a previous published motor control protocol
Study NCT03969537 — intervention group
Intervention type: OTHER
Intervention: Telemedicine follow-up visit
Description: Study participants will experience two telemedicine (live audio/video) visits.
Study NCT03838315 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neural Mobilization with Soft Tissue Mobilization
Description: Cervical Traction for 10mints 7%of body weight with 7 second hold time and 5 second rest time.~Hot Pack for 10mints. Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization. Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 10minute.~•Post isometric relaxation technique
Study NCT01784263 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Individual Cognitive Behavioral Therapy
Description: Therapists will work with families for 32 weekly sessions, each lasting 90 minutes (45 minutes with the child and 45 minutes with the family/parents), implementing the CBT manual for children with ASD (Wood et al., 2007).
Study NCT01784263 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Community Treatment
Description: In this condition, the child meets with a therapist for 32 weekly sessions, each 90 minutes. Therapists use an established manual to administer a standard community treatment.
Study NCT00520468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Erythropoietin
Description: 40,000 units injected under the skin (SQ) weekly
Study NCT00520468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporin A
Description: 300 mg (tablets) by mouth daily for 6 months
Study NCT00520468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: G-CSF
Description: 300 mcg injected under the skin (SQ) two times per week
Study NCT00520468 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: 60 mg per day for 7 days, taper over 1 month
Study NCT01271972 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nesvacumab (REGN910/ SAR307746)
Study NCT02375685 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Gevokizumab
Study NCT00087412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT03838315 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neural Mobilization without Soft Tissue Mobilization
Description: Cervical Traction for 10mints 7%of body weight with 7 second hold time and 5 second rest time.~* Hot Pack~* Neural mobilization technique includes Median, Radial and Ulnar nerve mobilization Frequency for neural mobilization is 3 sets of 10 repetitions for each and duration of 10minute.
Study NCT00087412 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00009893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Study NCT00009893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine hydrochloride
Study NCT00009893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Study NCT03526146 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral: Preventing Loss of Independence through Exercise (PLIE)
Description: PLIE is an integrative exercise program that focuses on training procedural memory for the ability to perform the movements that are most needed for daily function (e.g., transitioning safely from sitting to standing) while increasing mindful body awareness and encouraging social connection. It combines elements from a wide range of Eastern and Western exercise modalities, including occupational therapy, physical therapy, yoga, tai chi, Feldenkrais, Rosen Method, dance movement therapy and mindfulness meditation.
Study NCT03888690 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Virtual Reality Headset
Description: Standardized procedures, with or without Virtual Reality Headset.
Study NCT02826499 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pediguard
Description: It is a guide for the perforation of the pedicular channel, with a probe at its extremity. This probe allows a real time measurement of the electric conductivity of the tissues that are being crossed. The conductivity measure is translated in a sound signal. Because the cortical bone has a low conductivity, the probe will emit a low intensity sound signal. The cancellous bone has a medium conductivity. Therefore, the probe will emit a medium sound signal. However, in the event of a breach in the pedicular cortical, as blood and periost have a high conductibility, the probe will emit a intense, rapid pace, sound signal.The Pediguard technique helps thus to anticipate a cortical effraction, by detecting the proximity of the cortical wall.
Study NCT02826499 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Fluoroscopy
Description: The placing of pedicular screws under fluoroscopic control is the most common technique as it is both reproducible and accessible. It is a two dimensional imaging technique. The profile incidence at the level of the spine is mostly used to spot the vertebral pedicle and the direction of the screw in the sagittal plane. However, there is no real control of the direction of the pedicular screw in the horizontal or frontal plane and it is an irradiating imaging technique.
Study NCT02826499 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Fluoroscopy
Description: The placing of pedicular screws under fluoroscopic control is the most common technique as it is both reproducible and accessible. It is a two dimensional imaging technique. The profile incidence at the level of the spine is mostly used to spot the vertebral pedicle and the direction of the screw in the sagittal plane. However, there is no real control of the direction of the pedicular screw in the horizontal or frontal plane and it is an irradiating imaging technique.
Study NCT01793935 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sensoril®
Description: Sensoril® is a proprietary extract of Withania Somnifera. Each Sensoril® capsules will contain 250 mg of standardized extract of Withania Somnifera
Study NCT01793935 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Each Placebo capsule comprises inert ingredients; microcrystalline cellulose NF 102, croscarmellose Sodium NF, silicon Dioxide, Fumed NF (Cab-0-sil), magnesium sterate, NF matched in appearance and fill weight to Sensoril® capsules. Moreover, based on past experience, we will expose the placebo capsules to covered sachets containing Sensoril, so that the smell permeates the placebo capsules which then smell like the Sensoril capsules.
Study NCT02087592 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured exercise training plus mediterranean diet
Study NCT01363440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI; EYLEA®; BAY86-5321)
Study NCT03552705 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 5-day course of oral standard adult oral tranexamic acid dosage of 1300 mg taken 3 times a day (3900 mg/day) and intravenous tranexamic acid during ACL reconstruction surgery (1 gram of iv TXA just prior to incision and 1 gram of iv TXA just prior to wound closure)
Study NCT01197248 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Cystocele plication
Description: placement of sutures over the pubocervical fascia during the cystocele repair
Study NCT01363440 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Macular Laser Photocoagulation
Description: Laser therapy
Study NCT02981251 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health education with support by trained female health volunteer
Description: Along with usual care four sessions of interactive health education will be provided to the participants by medical officer and/or registered nurse based on a syllabus for six months. Trained female female health volunteer will motivate the participants through their home visit twice a month where they will monitor blood pressure and counsel the family members to support the patient.
Study NCT03695094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Padsevonil
Description: Padsevonil (PSL) will be dosed to steady state and the effect of background therapies on pharmacokinetics will be assessed
Study NCT03695094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxcarbazepine
Description: Concomitant administration of oxcarbazepine (OXC) at therapeutic dosage
Study NCT03695094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Concomitant administration of levetiracetam (LEV) at therapeutic dosage
Study NCT03695094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lamotrigine
Description: Concomitant administration of lamotrigine (LTG) at therapeutic dosage
Study NCT03695094 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brivaracetam
Description: Concomitant administration of brivaracetam (BRV) at therapeutic dosage
Study NCT02323334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3202626
Description: administered orally
Study NCT01197248 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: No Plication
Description: Avoid sutures over pubocervical fascia during cystocele plication
Study NCT02323334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LY3202626
Description: administered orally
Study NCT02532439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HR-pQCT
Description: Xtreme CT® device is a high resolution peripheral quantitative computed tomography (HR-pQCT) used to measure bone density and quantify the bone architecture to 3D at the extremities of the human body.~For the study, the device will be used to assess bone density and microarchitecture at the forearm and shin for a systemic effect. In rheumatoid arthritis, bone density and microarchitecture will also be measured at the metacarpophalangeal.
Study NCT02532439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DEXA
Description: The Lunar Dual Energy X-ray Absorptiometry (DEXA) is a third generation multi-captor DEXA device that allow short duration measurements. It measures Bone Mineral Density (BMD) at the spine and the femoral neck
Study NCT02532439 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: pQCT
Description: Peripheral Quantitative Computed Tomography (pQCT) will be performed and measure bone and muscle parameters.
Study NCT01480544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Treatment 1
Description: Physicians will receive financial incentives for improving the quality of obstetric and neonatal care provided to mothers and newborns as reported by mothers during household interviews.
Study NCT01480544 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Experimental: Treatment 2
Description: Physicians will receive financial incentives for improving maternal and neonatal health outcomes as reported by mothers during household interviews.
Study NCT04131842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External focus of attention visual feedback
Description: Patients will receive external focus of attention visual feedback during the impairment-based rehabilitation program.
Study NCT04131842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External focus of attention auditory feedback
Description: Patients will receive external focus of attention auditory feedback during the impairment-based rehabilitation program.
Study NCT04131842 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Internal focus of attention video feedback
Description: Patients will receive internal focus of attention visual feedback during the impairment-based rehabilitation program.
Study NCT04131842 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: No feedback
Description: Patients will receive no feedback during the impairment-based rehabilitation program.
Study NCT03206008 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Magnesium Sulfate
Study NCT03206008 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal saline
Description: Placebo
Study NCT03913559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inotuzumab ozogamicin
Description: dose: 0.5 mg/m2 IV over 60 minutes, days: 1, 8 and 15 every 4 weeks (28 days per cycle) for up to 6 cycles.
Study NCT03913559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Intrathecal (IT) therapy
Study NCT03913559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Intrathecal (IT) therapy
Study NCT03913559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Intrathecal (IT) therapy
Study NCT02367222 — intervention group
Intervention type: OTHER
Intervention: Exposed to Arepanrix™ Cohort
Description: Demographic characteristics such as age, sex, area of residence, socio-economic status; medical history such as comorbidities, immune status, vaccine indication, receipt of other vaccines or medications and frequency of healthcare contacts, as well as information on pregnancy status and pre-existing conditions will be collected..
Study NCT02367222 — intervention group
Intervention type: OTHER
Intervention: Unexposed to Arepanrix™ Cohort
Description: Demographic characteristics such as age, sex, area of residence, socio-economic status; medical history such as comorbidities, immune status, vaccine indication, receipt of other vaccines or medications and frequency of healthcare contacts, as well as information on pregnancy status and pre-existing conditions will be collected.
Study NCT02941536 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Circulating tumor cells evaluation
Description: Sample collection of circulating tumor cells (CTC) before and 4-5 weeks after focal stereotactic radiotherapy in single (SRS) or fractionated (SFRT) dose.
Study NCT02569515 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epoetin Beta
Description: Initial dose: 3X30 IU/Kg body weight administered subcutaneously using RecoPen. Dosage could be increased by 3X20 IU/Kg every 4 weeks up to a maximum of 720 IU/Kg per week.
Study NCT02265913 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acyclovir 5 percent (Perrigo)
Study NCT02265913 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Acyclovir 5 percent (Reference)
Study NCT02265913 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo cream
Study NCT00042809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: paclitaxel
Description: Given IV
Study NCT00042809 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT00042809 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT00042809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT00042809 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT03127449 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Alflutinib
Description: patients take Alflutinib orally once per day at different dose
Study NCT01377493 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: chewing gum
Description: chewing gum containing no active ingredients, or Ca-P bioavailable ions, or Ca-P and F bioavailable ions
Study NCT01377493 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: chewing gum
Description: chewing gum containing no active ingredients, or Ca-P bioavailable ions, or Ca-P and F bioavailable ions
Study NCT03156530 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Auricular acupunture
Description: Evaluation of balance before, during and after applying of auricular acupuncture.
Study NCT03156530 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Control
Description: Not receive stimulation.
Study NCT00075881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT00075881 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT01149200 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TC-6499
Description: 5mg enteric-coated oral hard gelatin capsule, administered twice daily
Study NCT01149200 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo as enteric-coated oral hard gelatin capsule, administered twice daily
Study NCT00460993 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lunesta
Description: Both groups receive eszopiclone. Group 1 receives Lunesta (eszopiclone) in intervention weeks 1 and 2 followed by placebo in weeks 3 and 4.~Group 2 receives placebo in intervention weeks one and two followed by Lunesta (eszopiclone) in weeks 3 and 4.
Study NCT02323334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo (Part A, B, C)
Description: administered orally
Study NCT02323334 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Part A, B, C)
Description: administered orally
Study NCT02323334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: administered orally
Study NCT00748800 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Affect Management
Description: 5 session group intervention that focused on teaching affect management skills and included HIV prevention and sexual health training
Study NCT00748800 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: General Health Promotion
Description: 5 session group focused on delivering general health promotion information in didactic format
Study NCT04398966 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Prostatic Artery Embolization (HydroPearl® compressible microspheres)
Description: Embolic material
Study NCT02557789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lefamulin
Description: Lefamulin administered iv or orally in the fasted state and orally in the fed state
Study NCT03552705 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: 5-day course of oral placebo and intravenous saline during ACL reconstruction surgery
Study NCT01978275 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: stimulong 100, pajunk, germany
Description: simulating catheter
Study NCT03913559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Diphenhydramine
Description: 1 mg/kg (max 50 mg) IV
Study NCT03913559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acetaminophen
Description: 10 mg/kg (max 650 mg) PO x 1
Study NCT03913559 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Description: 1 mg/kg IV x 1
Study NCT01617967 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Patisiran
Description: Participants received a single dose of patisiran as an intravenous (IV) infusion on Day 0 and Day 28 (Q4W). Optional cohorts received an alternative dosing regimen (once every 3 weeks \[Q3W\]: Day 0 and Day 21) and an alternative premedication regimen.
Study NCT01552317 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: OxSalt care bundle
Description: A care bundle consisting of a range of features to help patients to reduce their salt intake such as reminder emails, phone calls and a website.
Study NCT03070119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tofersen
Description: Participants will receive a loading dose regimen followed by maintenance dosing.